Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "L773:1040 8428 OR L773:1879 0461 "

Sökning: L773:1040 8428 OR L773:1879 0461

  • Resultat 1-10 av 32
  • [1]234Nästa
Sortera/gruppera träfflistan
  • Fitzpatrick, John M., et al. (författare)
  • Optimizing treatment for men with advanced prostate cancer : expert recommendations and the multidisciplinary approach
  • 2008
  • Ingår i: Critical reviews in oncology/hematology. - 1040-8428 .- 1879-0461. ; 68:Suppl.1, s. S9-S22
  • Forskningsöversikt (refereegranskat)abstract
    • A multidisciplinary panel of 20 international experts, including urologists, radiation oncologists, and medical oncologists, convened during the Advanced Prostate Cancer Multidisciplinary Team meeting in Rome, Italy, in January 2007, to discuss the multidisciplinary team approach and current patterns of care for patients with hormone-refractory prostate cancer (HRPC). During the meeting, the experts discussed several definitions currently used in prostate cancer management, including those for senior adult patients. In addition, the panel reviewed a series of patient case studies in order to provide feedback on current treatment practices and to identify possible strategies for best practice. It was stressed that treatment decisions for senior adult patients should not be based solely on patient age. Additionally, although historically treatment decisions for advanced prostate cancer have focused on palliative care, given the survival benefit associated with docetaxel-based chemotherapy across patient subgroups, more men are likely to be offered chemotherapy for advanced-stage disease in the future.
  • Gerwins, Pär, et al. (författare)
  • Function of fibroblast growth factors and vascular endothelial growth factors and their receptors in angiogenesis
  • 2000
  • Ingår i: Critical reviews in oncology/hematology. - 1040-8428 .- 1879-0461. ; 34:3, s. 185-194
  • Tidskriftsartikel (refereegranskat)abstract
    • Angiogenesis, formation of new vessels from pre-existing ones, results from stimulation of endothelial cells, which line the vessel wall. These cells will leave their resting state and start to digest the basement membrane, proliferate, migrate and eventually differentiate to form a hollow tube. All these steps can be induced by growth factors and this review will focus on two important types of angiogenic growth factors, vascular endothelial growth factor (VEGF; also denoted vascular permeability factor, VPF) and fibroblast growth factor (FGF). Both types of factors bind to cell surface expressed receptors, which are ligand-stimulatable tyrosine kinases. Binding of the growth factors to their receptors leads to activation of the intrinsic tyrosine kinase and signal transduction to downstream signalling cascades. This results in transcriptional changes and biological responses. The molecular aspects of signalling cascades critical for endothelial cell proliferation and migration are beginning to be delineated. In contrast, signalling cascades leading to endothelial cell differentiation remain to be determined. Angiogenesis is essential for a number of physiological events such as embryonic development, ovulation, and wound healing. It has become increasingly clear that a number of diseases depend on angiogenesis. For future development of therapeutic tools, it is important to understand the molecular mechanisms that regulate angiogenesis.
  • Högberg, Thomas, 1947-, et al. (författare)
  • Role of weekly paclitaxel in the treatment of advanced ovarian cancer
  • 2002
  • Ingår i: Critical reviews in oncology/hematology. - 1040-8428 .- 1879-0461. ; 44:SUPPL.
  • Tidskriftsartikel (refereegranskat)abstract
    • Dose-dense weekly administration of paclitaxel has the potential advantage of allowing a larger percentage of cancer cells to enter the vulnerable phase of their cell cycle when cytotoxic paclitaxel concentrations are present. The lower doses and shorter infusion times used with weekly dosing should also minimize bone marrow suppression and other toxicities associated with standard paclitaxel 3-weekly administration. Clinical studies have confirmed that paclitaxel can be safely delivered on a weekly schedule as a 1-h infusion to patients with advanced ovarian cancer. Weekly administration of paclitaxel also appears to be better tolerated than 3-weekly administration. Single-agent weekly paclitaxel is associated with response rates of 20-65%. Combination therapy with weekly paclitaxel has mainly involved carboplatin and response rates with such regimens range from 60-88%. Triple-drug combination therapy has produced response rates of 42-67.5%. Such therapy has included weekly paclitaxel in combination with carboplatin/cisplatin plus topotecan, and carboplatin plus doxorubicin. In an attempt to avoid problems with high corticosteroid doses, dexamethasone doses of 10 and 8 mg have been used successfully in premedication regimens for weekly paclitaxel in ovarian cancer. ⌐ 2002 Elsevier Science Ireland Ltd. All rights reserved.
  • Ranieri, G., et al. (författare)
  • A model of study for human cancer : Spontaneous occurring tumors in dogs. Biological features and translation for new anticancer therapies
  • 2013
  • Ingår i: Critical reviews in oncology/hematology. - 1040-8428 .- 1879-0461. ; 88:1, s. 187-197
  • Forskningsöversikt (refereegranskat)abstract
    • Murine cancer models have been extremely useful for analyzing the biology of pathways involved in cancer initiation, promotion, and progression. Interestingly, several murine cancer models also exhibit heterogeneity, genomic instability and an intact immune system. However, they do not adequately represent several features that define cancer in humans, including long periods of latency, the complex biology of cancer recurrence and metastasis and outcomes to novel therapies. Therefore, additional models that better investigate the human disease are needed. In the pet population, with special references to the dog, cancer is a spontaneous disease and dogs naturally develop cancers that share many characteristics with human malignancies More than 40 years ago, optimization of bone marrow transplantation protocols was undertaken in dogs and recently novel targeted therapies such as liposomal muramyl tripeptide phosphatidylethanolamine and several tyrosine kinase inhibitors, namely masitinib (AB1010) and toceranib phosphate (SU11654), have been developed to treat dog tumors which have then been translated to human clinical trials. In this review article, we will analyze biological data from dog tumors and comparative features with human tumors, and new therapeutic approaches translated from dog to human cancer.
  • van Leeuwen, Barbara L., et al. (författare)
  • The effect of age and gender on outcome after treatment for colon carcinoma : A population-based study in the Uppsala and Stockholm region
  • 2008
  • Ingår i: Critical reviews in oncology/hematology. - : Elsevier. - 1040-8428 .- 1879-0461. ; 67:3, s. 229-236
  • Forskningsöversikt (refereegranskat)abstract
    • RATIONALE: The aim of this study was to assess whether there are differences in treatment strategy and outcome between different age cohorts among men and women with colon cancer. METHODS: All patients with colon cancer included in the regional quality registry in Uppsala/Orebro and Stockholm between 1996 and December 2004 were analysed (n=11002). Patients were divided into three age categories: < or =65 years, 66-80 years and >80 years. RESULTS: Overall and cancer-specific survival decreased with increasing age for stages II and III colon cancer but was not influenced by gender. Older patients with stage III tumours were less likely to be referred for chemotherapeutic treatment and there was a decrease in cancer-specific survival with increasing age, from 63.7% to 51.0% to 38.4% in the three age groups. Postoperative morbidity and the number of reoperations was significantly higher in men than in women. CONCLUSION: The present study shows lower cancer-specific survival among older patients than among younger patients. Gender was not a prognostic factor in cancer-specific survival.
  • Gahrton, G, et al. (författare)
  • High-dose treatment of multiple myeloma
  • 1999
  • Ingår i: Critical reviews in oncology/hematology. - 1040-8428. ; 30:2, s. 173-180
  • Tidskriftsartikel (refereegranskat)
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 32
  • [1]234Nästa

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy